Rune Christensen, co-founder of the Sky ecosystem and is widely known in the DeFi space. He has placed a large bet on rising oil prices. On-chain data shows thatRune Christensen, co-founder of the Sky ecosystem and is widely known in the DeFi space. He has placed a large bet on rising oil prices. On-chain data shows that

Rune Christensen Bets $5.9M on Oil Futures via Hyperliquid

2026/03/07 13:39
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

Rune Christensen, co-founder of the Sky ecosystem and is widely known in the DeFi space. He has placed a large bet on rising oil prices. On-chain data shows that Christensen recently opened a $5.89 million long position in crude oil futures. By using the decentralized derivatives platform Hyperliquid.

According to blockchain tracking data, Christensen first transferred about 4.01 million USDC to the platform. Shortly after, he used those funds to open leveraged positions. Those tied to global oil benchmarks. The move comes at a time when oil prices are climbing quickly. Ongoing geopolitical tensions, particularly the conflict involving Iran. That has pushed crude prices higher in recent weeks.

Large Oil Positions Opened Through Hyperliquid

Blockchain monitoring shows that Christensen’s position includes exposure to two major oil benchmarks. The largest portion of the trade focuses on West Texas Intermediate (WTI) crude oil. Data indicates that he opened roughly $5.71 million worth of WTI long contracts at an entry price near $92.08. The position reportedly uses 20x leverage. This increases both potential profits and risks.

In addition, Christensen opened a smaller position in Brent crude oil, the global oil benchmark. This trade is valued at about $180,000. It entered at roughly $92.16 using 7x leverage. Together, the two trades bring the total exposure close to $5.9 million. The positions suggest Rune Christensen expects oil prices to keep rising in the near term.

Rising Oil Prices Drive Market Interest

Oil markets have become increasingly volatile in recent weeks. Geopolitical tensions in the Middle East have raised concerns about potential supply disruptions. As a result, crude oil prices have climbed sharply. Brent crude initially surged more than 9% in late February. Since then, prices have continued to rise and recently moved closer to the $92 level.

Many traders now expect further price swings as the situation develops. In this environment, macro-focused traders often try to capture short term movements in commodities such as oil. Rune Christensen’s trade reflects this broader market sentiment. By opening a long position, he is essentially betting that oil prices will continue to increase.

DeFi Platforms Expand Access to Global Markets

The trade also shows how decentralized platforms are expanding access to financial markets. In the past, trading oil futures usually required access to traditional financial infrastructure. Institutional traders often needed prime brokerage accounts or complex legal agreements to enter commodity markets.

However, decentralized derivatives platforms are changing that landscape. Services like Hyperliquid allow traders to open positions quickly using crypto-based collateral. This system removes many of the traditional barriers to entry. As a result, traders can express views on global markets directly from blockchain-based platforms.

Rune Christensen’s oil trade reflects this shift. A macro bet that once required institutional connections now happens through DeFi. For many observers, this moment shows how crypto infrastructure is gradually merging with traditional financial markets. As these tools improve, more traders may begin using DeFi Platforms to trade assets far beyond crypto.

The post Rune Christensen Bets $5.9M on Oil Futures via Hyperliquid appeared first on Coinfomania.

Market Opportunity
THORChain Logo
THORChain Price(RUNE)
$0.422
$0.422$0.422
+1.44%
USD
THORChain (RUNE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09